HR Execs on the Move


 
At Townsend’s Louisiana treatment centers, we care for addiction as a single disease that is typically self-treated with alcohol, drugs, gambling, sex, compulsive overeating, and other substances.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.townsendla.com
  • 4540 Ambassador Caffery Pkwy Ste c110
    Lafayette, LA USA 70508
  • Phone: 800.504.1714

Executives

Name Title Contact Details

Similar Companies

Advanced Diagnostic Group

Advanced Diagnostic Group is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Roche NimbleGen

Roche NimbleGen, Inc. is a Madison, WI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Correlogic Systems

Correlogic Systems is a Germantown, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aravive

Aravive, Inc., is a clinical stage biotechnology company focused on developing new therapies that target important survival pathways for both solid tumors as well as hematologic malignancies. Our primary therapeutic focus is the GAS6-AXL pathway, where AXL receptor signaling plays a critical role in multiple types of malignancies by promoting metastasis and cancer cell survival. Our technology, originated in the laboratories of Drs. Amato Giaccia and his colleagues at Stanford University, uses genetic screening to identify critical targets for the development of therapeutic molecules for cancer therapy while sparing healthy cells. This strategy is designed to enable us to interrupt oncogenic signals and, using our high-affinity decoy receptors, outcompete cancer`s ability to grow, metastasize and acquire resistance to treatments. We believe our unique cancer therapies may hold promise as a monotherapy or in combination with other cancer treatments, augmenting the anti-tumor activity of radiotherapy, chemotherapy, immuno-therapeutics and cancer vaccines. By targeting advanced or metastatic disease, our approach has the potential to significantly improve survival rates while simultaneously reducing toxicity in cancer patients.